What the warnings say in three regions
Section 5.2 of the US label covers acute pancreatitis of every degree, including haemorrhagic and necrotising forms in which the pancreas bleeds or tissue dies, and notes that some cases have been fatal. These have been seen in people taking GLP-1 receptor agonists or Mounjaro® [1]. Prescribers are told to look out for belly pain that is severe or will not settle, which may travel to the back and may come with nausea or vomiting, and to stop Mounjaro® when pancreatitis is suspected [1].
The European and Canadian documents add two points. Tirzepatide was not tested in people with earlier pancreatitis and should be used cautiously in them, and once pancreatitis is confirmed it should not be started again [3][4]. The European information rates acute pancreatitis as “uncommon”, up to 1 person in 100, while Canada’s patient information lists it as rare [3][4].
Confirmed cases in the trials
Section 6.1 reports pancreatitis as events confirmed by adjudication: each suspected case was reviewed against set criteria before being counted. Because trials differed in length, the result is expressed per 100 years of exposure, the number of people affected for every 100 years of combined time on treatment [1]. Canada gives the same figures as 0.2% of people on Mounjaro® against 0.1% on comparators [4].
| Group | Events | People | People per 100 years of exposure |
|---|---|---|---|
| Mounjaro® [1] | 14 | 13 | 0.23 |
| Comparator treatments [1] | 3 | 3 | 0.11 |
What larger analyses found
The comparator group in the label is not placebo alone; across the diabetes trials, Mounjaro® was compared with placebo, semaglutide 1 mg and two basal insulins [1]. Meta-analyses pooling more trials point the same way and do not show a clear excess. A 2023 analysis of nine trials found a risk ratio of 1.46 for pancreatitis against all comparators, not statistically significant [7]. A 2024 analysis of 17 trials with 14,645 people found no significant difference from placebo at any dose, and risks comparable with insulin and GLP-1 receptor agonists [5].
A 2026 dose-response analysis of 19 trials with 15,471 people found acute pancreatitis in 0.22% overall, with no meaningful difference between 5, 10 and 15 mg, and age and sex did not change the picture [6]. Its authors note that all the trials were industry-funded with short to moderate follow-up, so precision remains limited [6]. After approval, the US label lists acute, haemorrhagic and necrotising pancreatitis, sometimes fatal, among voluntary reports, which carry no frequency [1].
Amylase and lipase: a raised result on its own
Amylase and lipase are digestive enzymes made by the pancreas. In the US placebo-controlled diabetes trials, average pancreatic amylase rose 33% to 38% from baseline and lipase 31% to 42% on Mounjaro®, against 4% and no change on placebo; in SURPASS-CVOT the average rises were 29% and 28% [1]. The European information reports average lipase rises of 32% to 39% in weight-management, sleep apnoea and heart failure trials [3].
Canada counts how many people had values above three times the upper limit of normal: for lipase, 5.4% to 6.8% on Mounjaro® against 2.6% on placebo, and 7.7% to 9.4% in the seven-trial pool [4]. Both Europe and Canada state that, without other signs and symptoms, raised enzymes alone do not predict pancreatitis [3][4]. MedlinePlus notes that lipase is one of the blood tests used, with symptoms and examination, when pancreatitis is suspected [10].
Why tirzepatide might affect the pancreas
What the labels support: the European information notes that GIP and GLP-1 receptors are present on the hormone-producing cells of the pancreas, among other tissues [3]. Neither the US nor the European label proposes a mechanism linking tirzepatide to pancreatitis; the warning is based on cases seen with the drug class and Mounjaro® itself [1][3].
General background: MedlinePlus explains that acute pancreatitis happens when digestive enzymes become active inside the pancreas instead of in the intestine, causing swelling, bleeding and damage [10]. Whether tirzepatide raises the risk directly, or acts through other routes such as gallstones, has not been established.
Other causes of pancreatitis
The NIH lists gallstones as the most common cause of acute pancreatitis, followed by heavy alcohol use, genetic disorders and some medicines [8]. MedlinePlus adds very high triglycerides, certain medicines including estrogens, corticosteroids, thiazides and azathioprine, procedures on the bile ducts, injury and some infections [10].
The gallstone link matters for Mounjaro®, because gallbladder disease is a separate warning on the same label [1]. Smoking and alcohol both raise the chance of pancreatitis, and the NIH strongly advises people who have had it to stop both [9].
Before starting, and if pain begins
- Before starting, tell your provider about any current or past pancreas problems; the Medication Guide asks for this [2].
- The NIH describes acute pancreatitis pain as starting slowly or suddenly in the upper abdomen, sometimes spreading to the back, and lasting for days, often with fever, nausea, vomiting, a fast heartbeat and a swollen or tender belly [8].
- MedlinePlus adds that the pain may worsen after eating, especially fatty food, may be worse lying flat and may spread below the left shoulder blade [10].
- If severe stomach pain sets in and keeps going, with or without nausea or vomiting, stop Mounjaro® and call your provider right away [2].
- If pancreatitis is confirmed, European and Canadian guidance is not to restart tirzepatide; any decision about future treatment is your prescriber’s [3][4].
Ordinary stomach pain is not the same
Abdominal pain is also a common, usually milder reaction on Mounjaro®: in the adult placebo-controlled trials, 5% to 6% reported it against 4% on placebo [1]. What marks the warning sign is pain that is severe, does not let up and may reach the back, especially with vomiting, fever or a racing heart. If you are unsure which you have, the instruction for suspected pancreatitis is the one that applies until a clinician says otherwise.
Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that keeps going, with or without nausea or vomiting, sometimes felt in the back | Stop Mounjaro® and call your healthcare provider right away | Emergency | Medication Guide [2] |
| Severe or worsening belly pain with fever or chills, a fast heartbeat, shortness of breath or yellow skin | Seek care right away; emergency services if severe | Emergency | NIH [8] |
| Upper belly pain with nausea and vomiting that is not settling | Your healthcare provider, the same day | Today | Medication Guide [2]; NIH [8] |
| A raised amylase or lipase result without symptoms | Your prescriber, who interprets it with your symptoms | At your next appointment | EU product information [3] |
| A past episode of pancreatitis, before starting or continuing Mounjaro® | Your prescriber | At your next appointment | Medication Guide [2]; Canadian monograph [4] |
